Clinical Trials in Michigan

Showing 2521-2540 of 13,890 trials

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

NCT05887492

The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.

Non Small Cell Lung CancerSolid Tumors, AdultLung Cancer+1 more

Tango Therapeutics, Inc.126 participantsStarted Jun 2023

Santa Monica, California, United States • Denver, Colorado, United States • Sarasota, Florida, United States +10 more locations

COMPLETEDPhase 283 miles

Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

NCT04628936

This was an open-label study to evaluate the long-term efficacy and safety of KZR-616 in patients with active polymyositis (PM) or dermatomyositis (DM) who completed the double-blind treatment period of Study KZR-616-003, up to and including the Week 32 Visit, prior to the first dose of open-label KZR-616.

PolymyositisDermatomyositis

Kezar Life Sciences, Inc.18 participantsStarted Nov 2020

Beverly Hills, California, United States • Orange, California, United States • Miami, Florida, United States +7 more locations

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

Find Trials by Condition in Michigan

The Synergy Disc To Anterior Cervical Discectomy and Fusion

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

The Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Randomized Comparison of PARtial Wrist Fusion With or Without Triquetral Excision (PARTE)

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

Study of AVZO-021 in Patients With Advanced Solid Tumors

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

ImpRoving hEalth behaviourS for LIfe After ENdometrial CancEr Trial

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

MARGetuximab Or Trastuzumab (MARGOT)

Natural History Study Protocol in PMM2-CDG (CDG-Ia)

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site